Skip to Content

Catalent Inc - Stock Quote CTLT

Rating as of

Morningstar's Catalent Inc Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Narrow-Moat Catalent Reports Strong FY Q3 Results; Raising FVE to $98 on Positive Outlook

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman |

Catalent reported strong fiscal third-quarter results, highlighted by revenue of $1.27 billion, representing a 21% increase from the prior-year period. Investors reacted favorably to the results, sending the stock up nearly 11%. We expect outsourcing to Catalent and other large contract development and manufacturing organizations (CDMOs) will continue to incrementally increase driven by the complexities of biologics manufacturing. Catalent's largest segment, Biologics, reported healthy quarterly revenue of $698 million, a 30% increase from the prior-year period on a reported basis.

Read Full Analysis

Catalent Inc's Company Profile

Business Description

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

14 Schoolhouse Road
Somerset, NJ, 08873
T +1 732 537-6200
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Mar 31, 2022
Fiscal Year End Jun 30, 2022
Stock Type Aggressive Growth
Employees 17,300